A phase Ib/II study of regorafenib and paclitaxel in patients with beyond first-line advanced esophagogastric carcinoma (REPEAT)
Sign Up to like & getrecommendations! Published in 2022 at "Therapeutic Advances in Medical Oncology"
DOI: 10.1177/17588359221109196
Abstract: Purpose: Regorafenib monotherapy, a multikinase inhibitor of angiogenesis, tumor microenvironment, and tumorigenesis, showed promising results in gastric cancer. We aimed to assess the tolerability of regorafenib and paclitaxel in patients with advanced esophagogastric cancer (EGC)… read more here.
Keywords: first line; regorafenib paclitaxel; paclitaxel patients; cohort ... See more keywords
A phase 1b study of napabucasin plus weekly paclitaxel in patients with advanced thymoma and thymic carcinoma.
Sign Up to like & getrecommendations! Published in 2017 at "Journal of Clinical Oncology"
DOI: 10.1200/jco.2017.35.15_suppl.e20001
Abstract: e20001Background: Napabucasin is a first-in-class cancer stemness inhibitor, identified by its ability to inhibit STAT3-driven gene transcription and spherogenesis of cancer stem cells (Li et al PN... read more here.
Keywords: napabucasin plus; study napabucasin; paclitaxel patients; weekly paclitaxel ... See more keywords
Dose dense paclitaxel in patients with advanced liposarcoma: Subgroup analysis from a phase II trial.
Sign Up to like & getrecommendations! Published in 2018 at "Journal of Clinical Oncology"
DOI: 10.1200/jco.2018.36.15_suppl.e23557
Abstract: e23557Background: We previously reported outcomes in a prospective phase II trial evaluating the efficacy of dose dense paclitaxel in patients with advanced or metastatic soft tissue sarcomas. Recr... read more here.
Keywords: dense paclitaxel; paclitaxel patients; dose dense; patients advanced ... See more keywords